Approved Ligands

Pancuronium dibromide.

Pancuronium dibromide.

Paroxetine.

Paroxetine.

Pazopanib is a potent and selective multi-targeted tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (Flk-1), platelet-derived growth factor receptor (PDGFR) and c-kit, which are key proteins responsible for tumor

Pazopanib is a potent and selective multi-targeted tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (Flk-1), platelet-derived growth factor receptor (PDGFR) and c-kit, which are key proteins responsible for tumor

Pazopanib is a potent and selective multi-targeted tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (Flk-1), platelet-derived growth factor receptor (PDGFR) and c-kit, which are key proteins responsible for tumor

Pazopanib is a potent and selective multi-targeted tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (Flk-1), platelet-derived growth factor receptor (PDGFR) and c-kit, which are key proteins responsible for tumor

Pazopanib is a potent and selective multi-targeted tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (Flk-1), platelet-derived growth factor receptor (PDGFR) and c-kit, which are key proteins responsible for tumor

Pazopanib is a potent and selective multi-targeted tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (Flk-1), platelet-derived growth factor receptor (PDGFR) and c-kit, which are key proteins responsible for tumor

Pazopanib is a potent and selective multi-targeted tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (Flk-1), platelet-derived growth factor receptor (PDGFR) and c-kit, which are key proteins responsible for tumor

Pentostatin is a ring-expanded nucleoside (REN) that potently inhibits adenosine deaminase inhibitor, which leads to lymphocyte toxicity. Pentostatin is used as anticancer agent to treat leukemia (hairy cell leukemia and chronic lymphocytic